{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:21:59Z","timestamp":1793449319625,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T00:00:00Z","timestamp":1703894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ejpn.2023.12.006","type":"journal-article","created":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T11:22:05Z","timestamp":1703935325000},"page":"113-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Visual outcome measures in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2190-0650","authenticated-orcid":false,"given":"Flavia C.","family":"Gericke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James V.M.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Hackenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Gerth-Kahlert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejpn.2023.12.006_bib1","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1212\/NXI.0000000000000060","article-title":"MOG antibody-associated diseases","volume":"2","author":"Reindl","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.ejpn.2023.12.006_bib2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12974-021-02160-9","article-title":"Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well?","volume":"18","author":"Havla","year":"2021","journal-title":"J.\u00a0Neuroinflammation"},{"issue":"1","key":"10.1016\/j.ejpn.2023.12.006_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11940-019-0541-x","article-title":"Treatment Approaches for MOG-Ab-associated demyelination in children","volume":"21","author":"Hacohen","year":"2019","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.ejpn.2023.12.006_bib4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejpn.2020.10.007","article-title":"E.U. paediatric MOG consortium consensus: Part 4 - outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Bruijstens","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"21","key":"10.1016\/j.ejpn.2023.12.006_bib5","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ejpn.2023.12.006_bib6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ana.25291","article-title":"Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein","volume":"84","author":"Spadaro","year":"2018","journal-title":"Ann. Neurol."},{"issue":"9","key":"10.1016\/j.ejpn.2023.12.006_bib7","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.ejpn.2023.12.006_bib8","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/WCO.0000000000000813","article-title":"Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases","volume":"33","author":"Mader","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.ejpn.2023.12.006_bib9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ejpn.2020.10.006","article-title":"E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Bruijstens","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"6","key":"10.1016\/j.ejpn.2023.12.006_bib10","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/bjophthalmol-2018-312399","article-title":"Clinical characteristics and prognosis of myelin oligodendrocyte glycoprotein antibody-seropositive paediatric optic neuritis in China","volume":"103","author":"Song","year":"2019","journal-title":"Br. J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.ejpn.2023.12.006_bib11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/WCO.0000000000000766","article-title":"Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis","volume":"33","author":"Chen","year":"2020","journal-title":"Curr. Opin. Neurol."},{"issue":"12","key":"10.1016\/j.ejpn.2023.12.006_bib12","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/dmcn.13757","article-title":"Retinal nerve fibre layer thinning is associated with worse visual outcome after optic neuritis in children with a relapsing demyelinating syndrome","volume":"60","author":"Eyre","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ejpn.2023.12.006_bib13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejpn.2020.04.002","article-title":"High association of MOG-IgG antibodies in children with bilateral optic neuritis","volume":"27","author":"Wendel","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"3","key":"10.1016\/j.ejpn.2023.12.006_bib14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/bjo.58.3.158","article-title":"Factors involved in the production of amblyopia","volume":"58","author":"Von Noorden","year":"1974","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ejpn.2023.12.006_bib15","series-title":"High Resolution Imaging in Microscopy and Ophthalmology: New Frontiers in Biomedical Optics","first-page":"59","article-title":"Optical coherence tomography (OCT): Principle and Technical Realization","author":"Aumann","year":"2019"},{"issue":"1","key":"10.1016\/j.ejpn.2023.12.006_bib16","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1167\/iovs.17-22821","article-title":"Outer retinal Dysfunction in the absence of structural abnormalities in multiple sclerosis","volume":"59","author":"Hanson","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"9","key":"10.1016\/j.ejpn.2023.12.006_bib17","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S1474-4422(10)70168-X","article-title":"Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis","volume":"9","author":"Petzold","year":"2010","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2023.12.006_bib18","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients","volume":"13","author":"Pache","year":"2016","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.ejpn.2023.12.006_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.ejpn.2023.12.006_bib20","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1055\/a-1928-5117","article-title":"Neuro-ophthalmological presentation of optic neuritis in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"239","author":"Lin","year":"2022","journal-title":"Klin Monbl Augenheilkd"},{"issue":"3","key":"10.1016\/j.ejpn.2023.12.006_bib21","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/ana.26440","article-title":"Longitudinal retinal changes in MOGAD","volume":"92","author":"Oertel","year":"2022","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.ejpn.2023.12.006_bib22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1352458514538110","article-title":"Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria","volume":"21","author":"Schippling","year":"2015","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.ejpn.2023.12.006_bib23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/0883073819877334","article-title":"Clinical features and outcomes of pediatric monophasic and recurrent idiopathic optic neuritis","volume":"35","author":"Jonzzon","year":"2020","journal-title":"J.\u00a0Child Neurol."},{"issue":"15","key":"10.1016\/j.ejpn.2023.12.006_bib44","article-title":"Retinal layer segmentation in a pediatric normal group","volume":"54","author":"Pelz","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpn.2023.12.006_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.577987","article-title":"Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: presentation and outcomes of adults at a single center","volume":"373","author":"Sutton","year":"2022","journal-title":"J.\u00a0Neuroimmunol."},{"issue":"3","key":"10.1016\/j.ejpn.2023.12.006_bib25","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1474-4422(19)30488-0","article-title":"Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study","volume":"19","author":"Armangue","year":"2020","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2023.12.006_bib26","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.ejpn.2023.12.006_bib27","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1212\/NXI.0000000000000081","article-title":"Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children","volume":"2","author":"Hacohen","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"10.1016\/j.ejpn.2023.12.006_bib28","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/1352458519845112","article-title":"The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults","volume":"26","author":"de Mol","year":"2020","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.ejpn.2023.12.006_bib29","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/1352458515587751","article-title":"Clinical and MRI phenotype of children with MOG antibodies","volume":"22","author":"Fernandez-Carbonell","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.ejpn.2023.12.006_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.msard.2018.07.022","article-title":"Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders","volume":"26","author":"Konuskan","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.ejpn.2023.12.006_bib31","first-page":"33","article-title":"Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai, China","volume":"265","author":"Zhao","year":"2018","journal-title":"J.\u00a0Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2023.12.006_bib32","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.ejpn.2023.12.006_bib33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jneuroim.2017.01.007","article-title":"MOG-antibody associated demyelinating disease of the CNS: a clinical and pathological study in Chinese Han patients","volume":"305","author":"Zhou","year":"2017","journal-title":"J.\u00a0Neuroimmunol."},{"issue":"3","key":"10.1016\/j.ejpn.2023.12.006_bib34","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejpn.2023.12.006_bib35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejpn.2020.10.005","article-title":"E.U. paediatric MOG consortium consensus: Part 5 - treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Bruijstens","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.ejpn.2023.12.006_bib36","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.msard.2018.11.026","article-title":"Unique characteristics of optical coherence tomography (OCT) results and visual acuity testing in myelin oligodendrocyte glycoprotein (MOG) antibody positive pediatric patients","volume":"28","author":"Narayan","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.ejpn.2023.12.006_bib37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jns.2019.03.014","article-title":"Clinical characteristics and outcomes of myelin oligodendrocyte glycoprotein antibody-seropositive optic neuritis in varying age groups: a cohort study in China","volume":"400","author":"Song","year":"2019","journal-title":"J.\u00a0Neurol. Sci."},{"issue":"4","key":"10.1016\/j.ejpn.2023.12.006_bib38","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/WNO.0000000000000629","article-title":"Optimal intereye difference thresholds in retinal nerve fiber layer thickness for predicting a unilateral optic nerve lesion in multiple sclerosis","volume":"38","author":"Nolan","year":"2018","journal-title":"J.\u00a0Neuro Ophthalmol."},{"issue":"6","key":"10.1016\/j.ejpn.2023.12.006_bib39","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200035","article-title":"Temporal dynamics of MOG antibodies in children with acquired demyelinating syndrome","volume":"9","author":"Wendel","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.ejpn.2023.12.006_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/ana.26731","article-title":"Do early relapses predict the risk of long-term relapsing disease in an adult and paediatric cohort with MOGAD?","author":"Chen","year":"2023","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2023.12.006_bib41","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ana.25909","article-title":"Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"89","author":"Cobo-Calvo","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejpn.2023.12.006_bib42","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1038\/srep04687","article-title":"Immature visual neural system in children reflected by contrast sensitivity with adaptive optics correction","volume":"4","author":"Liu","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpn.2023.12.006_bib43","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.neubiorev.2020.02.028","article-title":"Neuroplasticity in adult human visual cortex","volume":"112","author":"Castaldi","year":"2020","journal-title":"Neurosci. Biobehav. Rev."}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379823001903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379823001903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:42:34Z","timestamp":1761072154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379823001903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":44,"alternative-id":["S1090379823001903"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2023.12.006","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Visual outcome measures in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2023.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.","name":"copyright","label":"Copyright"}]}}